Infantile-Onset Pompe Disease: Disease-Characteristics Research Report

Executive summary

Infantile-onset Pompe disease (IOPD) is the severe, early-onset end of the autosomal-recessive GAA deficiency spectrum. Near-absent lysosomal acid α-glucosidase activity causes glycogen accumulation, lysosomal and autophagic dysfunction, and rapidly progressive cardiomyopathy, generalized hypotonia, bulbar weakness, and respiratory failure. Without disease-specific treatment, classic IOPD is usually fatal during the first year of life. Enzyme-replacement therapy (ERT), newborn screening, and CRIM-guided immune-tolerance induction have transformed survival, although long-term survivors retain substantial skeletal-muscle, bulbar, auditory, respiratory, and possibly central-nervous-system morbidity. The most authoritative recent clinical synthesis is the November 2024 MetabERN pathway (DOI: 10.1186/s13023-024-03373-w). (parenti2024theeuropeanreference pages 2-4, moschetti2024mutationspectrumof pages 1-2, prater2012theemergingphenotype pages 1-3)

The following table provides a compact knowledge-base summary; the narrative below expands and qualifies each field.

Table: This table condenses key disease-knowledge-base fields for infantile-onset Pompe disease, including identifiers, genetics, phenotypes, mechanisms, diagnostics, epidemiology, treatment, and emerging translational research. It is designed as a compact reference with ontology suggestions, quantitative details, and cited evidence sources.

1. Disease information

Definition and classification

Pompe disease—glycogen storage disease type II—is a lysosomal glycogen-storage disorder caused by deficiency of acid α-glucosidase. Classic IOPD generally presents in the first weeks or months with hypertrophic cardiomyopathy and profound generalized hypotonia. “Non-classic” or atypical infantile Pompe disease presents in infancy, sometimes after six months but within approximately two years, and may have less prominent cardiomyopathy. This report treats IOPD as a clinical subtype of the broader Pompe disease entity rather than a genetically separate disorder. (parenti2024theeuropeanreference pages 2-4, moschetti2024mutationspectrumof pages 2-3, moschetti2024mutationspectrumof pages 1-2)

Identifiers and synonyms

• MONDO: MONDO:0009290, glycogen storage disease II. The available source maps this broad entity rather than a distinct IOPD-only MONDO record.
• OMIM: #232300, glycogen storage disease II/Pompe disease; causal gene GAA, OMIM *606800.
• Orphanet: ORPHA:365, glycogen storage disease due to acid maltase deficiency.
• ICD-10-CM: E74.02, Pompe disease.
• ICD-11: generally classified under glycogen-storage diseases/inborn errors of carbohydrate metabolism; local coding-browser verification is advised before database ingestion.
• MeSH: Glycogen Storage Disease Type II.
• Synonyms: Pompe disease, acid maltase deficiency, acid α-glucosidase deficiency, glycogenosis type II, GSD II, lysosomal glycogen-storage disease, infantile acid maltase deficiency, classic infantile Pompe disease.

Open Targets identifies GAA as the dominant disease-associated target for MONDO:0009290 and ORPHA:365, supported by human genetic literature including PMIDs 11071489, 16917947, 20080426, 18429042, 16782080, and 14695532. Other genes returned by broad association searches are not established causes of Pompe disease and should not be entered as causal genes. (OpenTargets Search: Pompe disease-GAA)

Evidence granularity

The information summarized here is principally aggregated disease-level evidence from guidelines, cohorts, trials, and reviews. It is not an extraction from individual electronic health records. Case reports, such as prenatal ERT, are explicitly labeled as single-patient evidence.

2. Etiology, risk, protection, and gene–environment interaction

Causal factor

The sole established primary cause is germline biallelic pathogenic or likely pathogenic variation in GAA, located on chromosome 17q25.3. GAA encodes lysosomal acid α-glucosidase, which hydrolyzes α-1,4- and α-1,6-linked glycogen to glucose. Severe alleles producing minimal or no residual enzyme generally cause IOPD; genotype–phenotype correlation remains imperfect because residual activity, protein production, immune response, and treatment timing modify expression. Variant classes include missense, nonsense, frameshift, canonical and noncanonical splice variants, small insertions/deletions, and exon-level or larger rearrangements. A 2024 review reported more than 911 disease-associated variants, whereas MetabERN cited 648 documented variants as of December 2020, illustrating continued database growth rather than a true discrepancy. (parenti2024theeuropeanreference pages 2-4, moschetti2024mutationspectrumof pages 1-2)

Genetic risk and modifiers

• Autosomal-recessive genotype: two disease-causing alleles are necessary; heterozygous carriers are generally asymptomatic.
• Residual GAA activity: near-absence favors classic IOPD; greater residual activity tends toward later onset.
• CRIM status: approximately one-third of infantile patients are reported as CRIM-negative. Absence of endogenous immunologically detectable GAA increases the risk of high, sustained anti-rhGAA antibodies and poor ERT response. Some CRIM-positive patients also develop clinically important antibodies. (parenti2024theeuropeanreference pages 2-4, moschetti2024mutationspectrumof pages 2-3)
• Treatment-related modifiers: younger age and lower disease burden at ERT initiation, adequate dosing, and prevention of deleterious antibodies improve outcomes. These are modifiers of prognosis rather than risk of inheriting disease.
• Founder/population effects: marked geographic variation, including very high frequency in French Guiana, indicates founder effects. Specific pathogenic and pseudodeficiency alleles also vary by ancestry.

No modifier gene has been validated sufficiently for routine clinical prediction. The weak Open Targets association with TTN should not be interpreted as evidence that TTN modifies or causes IOPD. (OpenTargets Search: Pompe disease-GAA)

Environmental, infectious, lifestyle, and protective factors

There is no credible evidence that toxins, infection, smoking, diet, alcohol, radiation, or occupation cause IOPD. Sex is not a causal risk factor, and both sexes should be affected approximately equally. Family history and consanguinity increase the probability of inheriting two familial alleles but do not alter the molecular mechanism.

No established genetic “protective allele” prevents disease in a person carrying two severe pathogenic alleles. Relative protection is conferred by residual-function genotypes and—clinically—presymptomatic diagnosis, immediate ERT, immune-tolerance induction when indicated, vaccination/infection prevention, respiratory support, safe nutrition, and rehabilitation. There is no established disease-specific gene–environment interaction. Intercurrent respiratory infection, fasting, malnutrition, or prolonged immobility may unmask or worsen limited cardiopulmonary reserve but are downstream stressors, not causes.

3. Phenotypes

Core phenotype map

The 2024 variant review describes severe progressive hypotonia, hypertrophic cardiomyopathy, respiratory insufficiency, and delayed or regressing motor development. The authors’ abstract-level framing is that IOPD includes a severe “floppy baby” phenotype. (moschetti2024mutationspectrumof pages 2-3)

In a human clinical series of 11 ERT-treated long-term survivors, median age was 8.0 years (range 5.4–12.0), seven were independently ambulatory, and all showed sustained cardiac improvement. Nevertheless, motor weakness, speech impairment, hearing loss, dysphagia/aspiration risk, osteopenia, and GERD remained. Thus ERT changes—not eliminates—the phenotype. (prater2012theemergingphenotype pages 1-3)

Disease-specific pediatric quality-of-life estimates remain less standardized than motor, respiratory, and survival endpoints. The practical burden includes repeated lifelong infusions, ventilatory or feeding support, impaired mobility and communication, frequent specialist visits, caregiver time, and uncertainty about long-term neurologic outcomes.

4. Genetic and molecular information

Gene and protein

• Gene: GAA; HGNC:4065; Ensembl ENSG00000171298.
• Protein: lysosomal acid α-glucosidase/acid maltase; synthesized as a precursor, mannose-6-phosphate–targeted to lysosomes, and proteolytically matured.
• Origin: constitutional/germline. Somatic mutation is not a recognized cause.
• Functional effect: overwhelmingly loss of function—reduced synthesis, misfolding, defective trafficking or processing, instability, or reduced catalytic activity. Gain-of-function and dominant-negative mechanisms are not established.

Variant interpretation and testing cautions

Pathogenicity should be assigned using ACMG/AMP criteria integrating allele frequency, segregation, phenotype, enzyme activity, RNA/protein consequences, functional studies, and curated databases. Pseudodeficiency alleles can lower in-vitro activity against assay substrates without clinical Pompe disease, particularly complicating newborn screening. A VUS plus low DBS activity is not sufficient by itself for diagnosis.

The 2024 Italian study screened 2,934 symptomatic subjects, finding 39 with low enzyme activity and two causative GAA variants and 22 with variants of uncertain significance. This demonstrates the need to couple biochemistry with complete genetic interpretation. (moschetti2024mutationspectrumof pages 2-3)

Population allele frequencies are variant-specific. Severe IOPD alleles are individually rare. In a 2024 gnomAD-based analysis across recessive neuromuscular diseases, GAA had the highest estimated carrier frequency, 1.3%, and c.-32-13T>G had global allele frequency 0.0033; that splice variant is primarily associated with late-onset disease and should not be used as an IOPD-specific frequency estimate.

CRIM and epigenetics

CRIM is a protein-expression phenotype, not an independent gene. It may be predicted from well-characterized variants or measured by Western blot/protein methods. CRIM-negative status strongly informs immunomodulation. No reproducible disease-defining DNA-methylation, histone, or chromatin signature is currently used clinically. There is likewise no characteristic chromosomal aneuploidy or translocation; exon-level GAA deletions/duplications are sequence-level structural variants and should be sought when sequencing finds fewer than two explanatory alleles.

5. Environmental information

IOPD is not infectious, toxic, occupational, or lifestyle-mediated. No pathogen is causal or transmissible, and there is no zoonotic risk. Respiratory infections can cause acute deterioration because respiratory muscle reserve and airway clearance are poor. Sedentary behavior is generally a consequence of weakness; carefully prescribed activity may preserve function, whereas exhaustion or eccentric overload should be avoided. Adequate calories and protein, aspiration prevention, vaccination, and prompt infection treatment are supportive—not curative—interventions.

6. Mechanism and pathophysiology

Causal chain

1. Upstream genetic defect: biallelic GAA loss-of-function.
2. Biochemical defect: deficient lysosomal hydrolysis of glycogen to glucose.
3. Primary storage: glycogen accumulates in lysosomes of cardiomyocytes, skeletal and smooth muscle cells, vascular cells, and neural populations.
4. Organelle injury: lysosomes enlarge; membrane integrity and trafficking deteriorate. Glycogen and cellular debris may escape into cytoplasm.
5. Autophagic pathology: impaired autophagosome–lysosome processing produces autophagic buildup that disrupts sarcomeres and can impede uptake/trafficking of infused enzyme.
6. Secondary injury: mitochondrial dysfunction, altered calcium/energy homeostasis, oxidative stress, inflammatory signaling, apoptosis and failed regeneration amplify damage.
7. Tissue manifestations: cardiomyocyte enlargement causes hypertrophic cardiomyopathy; myofiber destruction causes hypotonia and weakness; diaphragmatic and motor-neuron involvement causes respiratory failure; bulbar and hypoglossal-system involvement contributes to dysphagia and speech/airway dysfunction.

The 2024 MetabERN synthesis explicitly identifies glycogen/autophagic accumulation, mitochondrial dysfunction, and oxidative stress. The 2024 mutation review describes progression from small glycogen-filled lysosomes to enlargement and rupture with cytoplasmic glycogen and muscle damage. (parenti2024theeuropeanreference pages 2-4, moschetti2024mutationspectrumof pages 2-3)

Relevant ontology suggestions

• GO biological process: glycogen catabolic process GO:0005980; autophagy GO:0006914; lysosomal transport GO:0007041; response to oxidative stress GO:0006979; muscle contraction GO:0006936.
• GO cellular component: lysosome GO:0005764; autophagosome GO:0005776; mitochondrion GO:0005739; sarcomere GO:0030017.
• Cell Ontology: skeletal muscle cell CL:0000187; cardiomyocyte CL:0000746; smooth muscle cell CL:0000192; motor neuron CL:0000100; endothelial cell CL:0000115; macrophage CL:0000235.

Immunity

Immune involvement is mainly iatrogenic immunogenicity to recombinant GAA rather than autoimmunity. CRIM-negative patients recognize rhGAA as foreign and are particularly susceptible to high sustained antibodies, reduced enzyme exposure, and poor clinical response. Prophylactic B-cell/T-cell–directed immune-tolerance induction is therefore a central part of precision care. Approximately one-third of infantile patients may be CRIM-negative. (parenti2024theeuropeanreference pages 2-4, moschetti2024mutationspectrumof pages 2-3)

Molecular profiling and advanced technologies

Human IOPD-specific single-cell, spatial, proteomic, lipidomic, and metabolomic datasets remain limited. A 2024 single-nucleus/spatial-transcriptomic study was in late-onset Pompe muscle, not IOPD; it found increased slow/regenerative fibers and macrophages, early reduction of glycolytic genes, increased lipid/amino-acid metabolism, increased autophagy genes, reduced ribosomal/mitochondrial programs, defective oxidative phosphorylation, and inflammation/apoptosis in vacuolated fibers. These pathways are biologically relevant but should not be entered as directly proven IOPD signatures without validation.

Preclinical multi-omics provides stronger mechanistic than diagnostic evidence. In Pompe mice, selective GYS1 inhibition corrected biochemical, metabolomic, and transcriptomic abnormalities as glycogen was lowered. No omics assay is currently a routine diagnostic standard for IOPD.

7. Anatomical structures affected

Organ and system level

• Primary: heart, skeletal muscle, diaphragm and other respiratory muscles, bulbar/oropharyngeal musculature.
• Additional: smooth muscle, peripheral and central motor systems, vasculature, liver, hearing apparatus, bone secondarily through immobility/nutrition.
• Systems: cardiovascular, neuromuscular, respiratory, gastrointestinal/nutritional, auditory, skeletal, and increasingly recognized CNS involvement.

Tissue, cell, and subcellular localization

Cardiomyocytes and skeletal myofibers are the major clinically damaged cells; motor neurons, smooth-muscle cells, endothelial cells and pericytes can also store glycogen. The key subcellular compartment is the lysosome, with downstream autophagosomal, mitochondrial and sarcomeric disruption. The 2024 review specifically identifies smooth and skeletal muscle, endothelial cells, motor neurons, and heart as involved. (moschetti2024mutationspectrumof pages 2-3)

Suggested UBERON terms include heart UBERON:0000948, skeletal muscle tissue UBERON:0001134, diaphragm UBERON:0001103, tongue UBERON:0001723, liver UBERON:0002107, spinal cord UBERON:0002240, and brainstem UBERON:0002298. Manifestations are generally bilateral/systemic rather than lateralized.

8. Temporal development

Classic IOPD is congenital in molecular origin and likely begins prenatally, although obvious clinical signs usually emerge over the first weeks or months. Onset is chronic-progressive rather than episodic. Untreated stages can be conceptualized as: early hypotonia/feeding difficulty and cardiac hypertrophy; progressive motor failure and respiratory infections; then ventilator dependence, heart/respiratory failure, and death. There is no spontaneous remission.

The critical therapeutic window is before substantial irreversible muscle, motor-neuron, and cardiac injury. Newborn screening and family-based prenatal diagnosis shift treatment toward this window. The prenatal ERT case supports prenatal substrate accumulation: the investigators opened their abstract with, “organ damage starts in utero.” (cohen2022inuteroenzymereplacement pages 12-14)

ERT induces rapid cardiac improvement more reliably than complete skeletal-muscle recovery. Disease remains lifelong and progressive residual pathology may emerge even when cardiomyopathy resolves.

9. Inheritance and population

Inheritance counseling

Inheritance is autosomal recessive. For two confirmed carrier parents, each pregnancy has a 25% probability of an affected child, 50% probability of an unaffected carrier, and 25% probability of an unaffected non-carrier. Penetrance for two severe IOPD-causing alleles is expected to be high, but age and severity vary. There is no genetic anticipation. Germline mosaicism is theoretically possible but is not a major established contributor; parental testing is still important when variants appear de novo. Consanguinity raises the chance that both parents carry the same rare allele.

Epidemiology

MetabERN reports historical overall incidence estimates of approximately 1:40,000–1:146,000, compared with approximately 1:8,684–1:23,596 in newborn-screened populations. Reported birth prevalence is around 1:17,000 in Taiwan and as high as 1:2,000 in French Guiana. These figures usually encompass all Pompe phenotypes and should not be mislabeled as IOPD-only incidence. (parenti2024theeuropeanreference pages 2-4)

The 2023 Northeast Italy program screened about 250,000 newborns for four lysosomal disorders. There were 126 screen positives (0.051%), 51 confirmed affected, and a 40% positive predictive value across all four disorders; three infants with IOPD were identified and immediately treated. The combined four-disorder incidence was 1:4,874, not Pompe-specific incidence. (gragnaniello2023lightandshadows pages 1-2)

There is no consistent sex bias. Geographic and ethnic differences reflect allele frequencies, founder effects, pseudodeficiency alleles, screening design, and access to diagnosis.

10. Diagnostics

Recommended diagnostic sequence

1. Urgent biochemical screening: GAA activity in dried blood spot, preferably with an inhibitor/assay system that minimizes interference from maltase-glucoamylase.
2. Confirmation: repeat enzyme assay in leukocytes, lymphocytes, cultured fibroblasts, or another validated tissue.
3. Molecular confirmation: full GAA sequencing with deletion/duplication analysis; familial variant testing where known.
4. CRIM determination/prediction: from established genotype or protein testing; do not delay lifesaving ERT while awaiting prolonged work-up.
5. Baseline staging: ECG, echocardiography, cardiology review; oxygenation, blood gas where indicated, respiratory-muscle and sleep assessment; swallow/feeding evaluation; hearing assessment; motor/developmental evaluation.

The 2024 Italian review describes sequential DBS/fibroblast/muscle enzyme testing followed by complete GAA sequencing for low or borderline activity. (moschetti2024mutationspectrumof pages 2-3)

Biomarkers and clinical tests

• Enzyme: deficient acid α-glucosidase activity is the principal biochemical marker.
• Muscle injury: CK, AST, ALT and LDH are often elevated but nonspecific.
• Storage: urinary or plasma glucose tetrasaccharide, Glc4/Hex4, supports diagnosis and longitudinal response; values can be affected by age and other glycogen disorders.
• Cardiac: ECG may show short PR and high voltages; echocardiography quantifies hypertrophy and function.
• Respiratory: pulse oximetry alone may miss hypoventilation; capnography/blood gases, sleep study, cough strength and age-appropriate pulmonary testing are useful.
• Electrophysiology: EMG may show an irritable myopathy but is not required in a biochemically/genetically clear infant.
• Biopsy: vacuolated, PAS-positive glycogen-rich myofibers and lysosomal glycogen by electron microscopy; usually unnecessary when enzyme and molecular results are definitive.

Genomic modalities

Single-gene sequencing plus copy-number analysis is usually sufficient. A neuromuscular/cardiomyopathy panel, WES, or WGS is useful when the presentation is atypical or initial testing is negative; WGS may detect deep-intronic and structural variants. RNA sequencing can resolve suspected splice variants but is adjunctive. CMA, karyotype, FISH, mitochondrial DNA testing, and repeat-expansion testing are not routine unless another diagnosis is suspected.

Differential diagnosis

Key alternatives include spinal muscular atrophy, congenital muscular dystrophies/myopathies, Danon disease, PRKAG2 cardiomyopathy, mitochondrial disease, fatty-acid oxidation disorders, other glycogenoses, congenital disorders of glycosylation, sepsis, hypothyroidism, and structural/congenital cardiomyopathy. Cardiomyopathy plus marked hypotonia, macroglossia, elevated muscle enzymes, and very low GAA strongly favors IOPD.

Screening

Newborn screening measures GAA activity in DBS, often followed by second-tier biomarkers and rapid molecular testing. False positives arise from sample quality, pseudodeficiency, heterozygosity, and VUS; detection of late-onset genotypes creates counseling and follow-up challenges. The Italian program’s authors concluded that screening was feasible and effective but emphasized false positives and uncertain/late-onset findings. (gragnaniello2023lightandshadows pages 1-2)

11. Outcome and prognosis

Untreated course

Classic untreated IOPD is rapidly fatal, generally from cardiorespiratory failure during the first year; older natural-history series commonly place death or invasive ventilation by one to two years. The 2024 review characterizes untreated outcome as invariably fatal within one year. (moschetti2024mutationspectrumof pages 1-2)

Treated course

ERT substantially improves overall and ventilator-free survival, reverses cardiac hypertrophy, and permits motor milestone acquisition in many infants, especially when started presymptomatically. However, there is no reliable single five- or ten-year survival estimate applicable across genotype, CRIM status, start age, dose, and immune-management era.

In the 11-patient survivor cohort, all had cardiac improvement and seven walked independently, but residual weakness, speech and swallowing problems, hearing loss, osteopenia, and GERD were frequent. This is strong evidence that cardiac response does not equal multisystem cure. (prater2012theemergingphenotype pages 1-3)

Prognostic factors and biomarkers

Favorable factors are diagnosis through newborn/family screening, ERT before irreversible injury, CRIM positivity or successful immune tolerance, low anti-drug antibody titers, lower baseline cardiac/motor burden, and sustained biochemical response. Adverse factors include CRIM negativity without prophylactic immunomodulation, high sustained antibodies, delayed ERT, severe baseline ventilation/feeding dependence, and advanced muscle pathology. Serial LV mass, motor milestones, ventilation status, CK and Glc4/Hex4 are useful response/prognostic measures, but none is a fully validated standalone surrogate for long-term neurologic outcome.

12. Treatment

Disease-specific pharmacotherapy

Alglucosidase alfa is recombinant human GAA and the foundational standard of care. It is internalized through the cation-independent mannose-6-phosphate receptor and delivered to lysosomes. A conventional labeled regimen is 20 mg/kg intravenously every two weeks, although expert centers often use higher exposure—commonly 40 mg/kg weekly or every two weeks—in IOPD based on disease severity and emerging outcome data. Exact dosing must follow jurisdictional labeling and specialist protocols. Long-term survivors in one cohort received cumulative biweekly doses of 20–40 mg/kg. (prater2012theemergingphenotype pages 1-3)

Avalglucosidase alfa is glycoengineered with additional bis-mannose-6-phosphate moieties to enhance cellular uptake. It is a next-generation ERT with established use in Pompe disease in some jurisdictions and active pediatric/IOPD evaluation. Preclinical Pompe mice achieved stronger skeletal-muscle glycogen reduction and comparable heart/diaphragm clearance at fourfold lower dose than standard rhGAA. (unnisa2022genetherapydevelopments pages 2-3)

Suggested NCIT concepts are enzyme replacement therapy, alglucosidase alfa, avalglucosidase alfa, intravenous infusion, immunosuppressive therapy, physical therapy, occupational therapy, speech therapy, mechanical ventilation, and enteral nutrition; identifiers should be validated against the current NCIT release before ingestion.

Immune-tolerance induction

CRIM status should be established or predicted urgently. CRIM-negative infants generally receive prophylactic immune-tolerance induction at ERT initiation, commonly rituximab, methotrexate, and intravenous immunoglobulin in specialist protocols. Some high-risk CRIM-positive infants may also be considered. Anti-rhGAA IgG titers and clinical/biochemical response require serial monitoring. Established high sustained titers are harder to eradicate than to prevent.

Supportive and rehabilitative care

• Cardiac monitoring and cautious management of heart failure/arrhythmia; anesthesia requires a metabolic-cardiac team.
• Airway clearance, assisted cough, noninvasive ventilation, escalation to invasive ventilation when necessary, sleep evaluation, and prompt infection treatment.
• Swallow studies, texture adaptation, caloric/protein support, reflux treatment, and nasogastric or gastrostomy feeding when aspiration or growth failure warrants.
• Individualized PT/OT emphasizing positioning, contracture prevention, low-to-moderate submaximal activity, orthoses, mobility aids, and avoidance of overwork weakness.
• Speech-language therapy for feeding, dysarthria and augmentative communication.
• Hearing, vision, bone health, dental, developmental, educational, and psychosocial surveillance.

Surgery is not disease-modifying. Gastrostomy, tracheostomy, orthopedic procedures, and vascular access are supportive interventions selected case by case.

Adverse effects

ERT can cause infusion-associated reactions, anaphylaxis, pyrexia, rash and antibody formation. Cardiorespiratory instability during infusion is especially consequential in infants with advanced hypertrophic cardiomyopathy. Immunomodulation adds infection, cytopenia and vaccine-response risks.

Trials and experimental therapy

• Mini-COMET, NCT03019406: phase 2 pediatric IOPD study of avalglucosidase alfa in previously alglucosidase-treated patients; 22 participants; active, not recruiting in the retrieved registry record.
• Baby-COMET, NCT04910776: phase 3 avalglucosidase study in treatment-naïve IOPD; 17 participants; active, not recruiting.
• NCT06666413: phase 4 post-approval avalglucosidase study in Chinese IOPD; 13 planned participants; recruiting in the retrieved record.
• NCT05017402: observational study of higher-dose alglucosidase, 36 planned participants.

Gene-therapy platforms include in-vivo AAV liver-, muscle-, and CNS-directed expression and ex-vivo lentiviral HSPC therapy. Potential advantages are continuous enzyme secretion, cross-correction, immune tolerance, and CNS access; limitations include vector immunity, dose-related toxicity, pediatric growth-related dilution, redosing barriers, manufacturing, and uncertain durability. A 2023 review concluded: “Gene therapy for the treatment of patients with Pompe disease is feasible,” while emphasizing vector production, immune reactions and redosing. (leonastudillo2023currentavenuesof pages 11-12)

Prenatal ERT remains experimental. In a single CRIM-negative fetus treated in utero and then postnatally, cardiac function and age-appropriate motor development were normal at 13 months, biomarkers were normal, and feeding/growth were satisfactory. Placental pathology showed marked reduction of glycogen storage. This is proof of concept, not efficacy evidence from a controlled trial. DOI: 10.1056/NEJMoa2200587, published December 2022. (cohen2022inuteroenzymereplacement pages 12-14)

Substrate reduction: selective muscle glycogen synthase-1 inhibition is preclinical. MZ-101 reduced skeletal-muscle glycogen comparably to ERT in Pompe mice, while combination treatment was additive and normalized muscle glycogen; translation to infants remains unproven.

13. Prevention

Primary prevention through lifestyle or vaccination is not possible because the disorder is inherited. Relevant prevention levels are:

• Primary genetic prevention: preconception carrier testing in at-risk relatives/populations, genetic counseling, IVF with preimplantation genetic testing, and prenatal diagnosis by chorionic-villus sampling or amniocentesis for known familial variants.
• Secondary prevention: newborn screening, rapid confirmatory testing, presymptomatic ERT, and CRIM-guided immune tolerance. This is the most effective strategy for preventing irreversible organ damage.
• Tertiary prevention: vaccination, respiratory-infection precautions, airway clearance, aspiration prevention, adequate nutrition, contracture/osteopenia prevention, hearing support, and multidisciplinary surveillance.

Cascade testing should be offered to siblings and extended relatives. There is no disease-specific vaccine or prophylactic medication that prevents inheritance. Standard immunizations are important, but timing may need adjustment around rituximab or other immunosuppression.

14. Other species and natural disease

Pompe-like GAA deficiency occurs naturally in several species, including Japanese quail and reported cattle, dogs, cats, and sheep. Orthologous GAA is conserved, and the shared pathology is lysosomal glycogen accumulation with skeletal/cardiac muscle disease. Species-specific severity, neuroanatomy, immune responses and lifespan limit direct extrapolation.

A 2020 review catalogued 42 glycogen-storage-disease models overall: 26 genetically modified mouse models, 15 naturally occurring models spanning quail, cats, dogs, sheep, cattle and horses, and one genetically modified zebrafish. These totals cover all GSDs, not Pompe alone; Japanese quail is the best-known spontaneous Pompe model. There is no zoonotic transmission or cross-species contagion.

Suggested taxonomy entries include Homo sapiens NCBI Taxon 9606, Mus musculus 10090, Coturnix japonica 93934, Canis lupus familiaris 9615, Bos taurus 9913, Felis catus 9685, and Ovis aries 9940. Breed-specific VBO mapping requires variant-specific veterinary reports.

15. Model organisms and experimental systems

Gaa-knockout mice

The Gaa−/− mouse is the principal mammalian model. It reproduces systemic enzyme deficiency, glycogen accumulation, autophagic pathology, skeletal weakness and variable cardiac/respiratory disease. It is extensively used for ERT, AAV, immune-tolerance, glycogen-synthase inhibition and CNS-targeting studies. Limitations include differences from human infant cardiomyopathy, scale, immune responses, vector tropism, and lifespan.

Intrathecal or spinal AAV studies in Pompe mice have produced long-term neurologic/cardiac correction and increased ventilation. Chemogenetic activation of hypoglossal motoneurons has been used to dissect neural contributions to swallowing, speech-related and sleep-disordered-breathing phenotypes. These are model-organism findings, not clinical efficacy evidence. (leonastudillo2023currentavenuesof pages 11-12)

Large animals and nonhuman primates

Large animals better model systemic delivery, anatomy and dose scaling but are scarce. In AT845 studies, systemic muscle-directed AAV increased GAA, cleared glycogen and improved function in Gaa−/− mice. High-dose treatment in cynomolgus macaques caused anti-human-GAA immune inflammation and cardiac abnormalities, whereas macaque GAA did not, illustrating species-specific xenogeneic immunogenicity and limitations of toxicity prediction.

Cellular models

Patient fibroblasts, immortalized myoblasts, primary myotubes, CRISPR-engineered cells, and patient-derived iPSC cardiomyocytes/skeletal myocytes model enzyme processing, lysosomal storage, autophagy, cardiomyocyte hypertrophy, variant function and therapeutic rescue. Limitations include immature iPSC phenotypes, absent whole-organ mechanics/innervation, and incomplete modeling of systemic immunity and cross-correction. Muscle organoids and neuromuscular co-cultures are promising but not yet validated diagnostic platforms.

Recent developments and expert interpretation, 2023–2024

1. Standardized European pathway: the November 2024 MetabERN recommendations integrate diagnosis, ERT, immune management, respiratory/nutritional support and follow-up using AGREE II/GRADE methodology. This is the strongest recent authoritative care framework. DOI: 10.1186/s13023-024-03373-w. (parenti2024theeuropeanreference pages 2-4, parenti2024theeuropeanreference pages 22-23)
2. Variant expansion: the August 2024 GAA review documents continued allelic growth and reinforces paired biochemical/genetic diagnosis and CRIM-informed care. DOI: 10.3390/ijms25179139. (moschetti2024mutationspectrumof pages 2-3, moschetti2024mutationspectrumof pages 1-2)
3. Real-world newborn screening: Northeast Italy’s eight-year report showed operational feasibility at approximately 250,000 births, with three IOPD infants immediately treated, while quantifying false-positive/VUS challenges. Published December 2023; DOI: 10.3390/ijns10010003. (gragnaniello2023lightandshadows pages 1-2)
4. Gene therapy maturation: 2023–2024 reviews conclude that AAV and lentiviral platforms are clinically plausible but remain constrained by immunity, redosing, durability and CNS delivery. DOI: 10.1097/WCO.0000000000001187. (leonastudillo2023currentavenuesof pages 11-12, unnisa2022genetherapydevelopments pages 18-19)
5. Mechanism-directed combination therapy: 2024 preclinical work on selective GYS1 inhibition supports reducing glycogen synthesis alongside replacement of its degradation pathway. This is mechanistically compelling but not yet human IOPD therapy.

Evidence limitations

IOPD is ultra-rare, so many treatment and long-term phenotype data derive from small, nonrandomized cohorts, historical controls, registry studies, or case reports. Incidence estimates often combine infantile and late-onset Pompe disease. Omics studies are disproportionately based on late-onset muscle or animal models. Exact phenotype frequencies are therefore often qualitative rather than population percentages. Direct quotations above are limited to text available from retrieved abstracts; absence of a PMID in this report means it was not reliably present in the retrieved record, not that the article lacks one.

References

1. (parenti2024theeuropeanreference pages 2-4): Giancarlo Parenti, Simona Fecarotta, Marianna Alagia, Federica Attaianese, Alessandra Verde, Antonietta Tarallo, Vincenza Gragnaniello, Athanasia Ziagaki, Maria Jose’ Guimaraes, Patricio Aguiar, Andreas Hahn, Olga Azevedo, Maria Alice Donati, Beata Kiec-Wilk, Maurizio Scarpa, Nadine A. M. E. van der Beek, Mireja Del Toro Riera, Dominique P. Germain, Hidde Huidekoper, Johanna M. P. van den Hout, Ans T. van der Ploeg, Ivo Baric, Spyros Batzios, Nadia Belmatoug, Andrea Bordugo, Annet M. Bosch, Anais Brassier, Alberto Burlina, David Cassiman, Brigitte Chabrol, Efstathia Chronopoulou, Maria Luz Couce-Pico, Niklas Darin, Anibh M. Das, Francois G. Debray, Patrick Deegan, Luisa M. de Abreu Freire Diogo Matos, Javier De Las Heras Montero, Maja Di Rocco, Dries Dobbelaere, Francois Eyskens, Ana Ferreira, Ana M. Gaspar, Serena Gasperini, Antonio González-Meneses López, Salvatore Grosso, Nathalie Guffon-Fouilhoux, Julia Hennermann, Tarekegn G. Hiwot, Simon Jones, Sandra Kingma, Veroniki Komninaka, Elena Martín-Hernández, Esmeralda Martins, Diana Miclea, György Pfliegler, Esmeralda Rodrigues, Dariusz Rokicki, Dominique Roland, Frank Rutsch, Alessandro Salviati, Ivailo Tournev, Kurt Ullrich, Peter M. van Hasselt, Suresh Vijay, Natalie Weinhold, Peter Witters, and Jiri Zeman. The european reference network for metabolic diseases (metabern) clinical pathway recommendations for pompe disease (acid maltase deficiency, glycogen storage disease type ii). Orphanet Journal of Rare Diseases, Nov 2024. URL: https://doi.org/10.1186/s13023-024-03373-w, doi:10.1186/s13023-024-03373-w. This article has 28 citations and is from a peer-reviewed journal.

2. (moschetti2024mutationspectrumof pages 1-2): Marta Moschetti, Alessia Lo Curto, Miriam Giacomarra, Daniele Francofonte, Carmela Zizzo, Elisa Messina, Giovanni Duro, and Paolo Colomba. Mutation spectrum of gaa gene in pompe disease: current knowledge and results of an italian study. International Journal of Molecular Sciences, 25:9139, Aug 2024. URL: https://doi.org/10.3390/ijms25179139, doi:10.3390/ijms25179139. This article has 9 citations.

3. (prater2012theemergingphenotype pages 1-3): Sean N. Prater, Suhrad G. Banugaria, Stephanie M. DeArmey, Eleanor G. Botha, Erin M. Stege, Laura E. Case, Harrison N. Jones, Chanika Phornphutkul, Raymond Y. Wang, Sarah P. Young, and Priya S. Kishnani. The emerging phenotype of long-term survivors with infantile pompe disease. Sep 2012. URL: https://doi.org/10.1038/gim.2012.44, doi:10.1038/gim.2012.44. This article has 226 citations and is from a highest quality peer-reviewed journal.

4. (OpenTargets Search: Pompe disease-GAA): Open Targets Query (Pompe disease-GAA, 43 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

5. (moschetti2024mutationspectrumof pages 2-3): Marta Moschetti, Alessia Lo Curto, Miriam Giacomarra, Daniele Francofonte, Carmela Zizzo, Elisa Messina, Giovanni Duro, and Paolo Colomba. Mutation spectrum of gaa gene in pompe disease: current knowledge and results of an italian study. International Journal of Molecular Sciences, 25:9139, Aug 2024. URL: https://doi.org/10.3390/ijms25179139, doi:10.3390/ijms25179139. This article has 9 citations.

6. (uribecarretero2024lysosomaldysfunctionconnecting pages 14-16): Elisabet Uribe-Carretero, Verónica Rey, Jose Manuel Fuentes, and Isaac Tamargo-Gómez. Lysosomal dysfunction: connecting the dots in the landscape of human diseases. Biology, 13:34, Jan 2024. URL: https://doi.org/10.3390/biology13010034, doi:10.3390/biology13010034. This article has 15 citations.

7. (leonastudillo2023currentavenuesof pages 11-12): Carmen Leon-Astudillo, Prasad D. Trivedi, Ramon C. Sun, Matthew Gentry, Barry J. Byrne, and Manuela Corti. Current avenues of gene therapy in pompe disease. Jul 2023. URL: https://doi.org/10.1097/wco.0000000000001187, doi:10.1097/wco.0000000000001187. This article has 23 citations and is from a peer-reviewed journal.

8. (unnisa2022genetherapydevelopments pages 2-3): Zeenath Unnisa, John K. Yoon, Jeffrey W. Schindler, Chris Mason, and Niek P. van Til. Gene therapy developments for pompe disease. Biomedicines, 10:302, Jan 2022. URL: https://doi.org/10.3390/biomedicines10020302, doi:10.3390/biomedicines10020302. This article has 71 citations.

9. (gragnaniello2023lightandshadows pages 1-2): Vincenza Gragnaniello, Chiara Cazzorla, Daniela Gueraldi, Andrea Puma, Christian Loro, Elena Porcù, Maria Stornaiuolo, Paolo Miglioranza, Leonardo Salviati, Alessandro P Burlina, and Alberto B Burlina. Light and shadows in newborn screening for lysosomal storage disorders: eight years of experience in northeast italy. International Journal of Neonatal Screening, Dec 2023. URL: https://doi.org/10.3390/ijns10010003, doi:10.3390/ijns10010003. This article has 36 citations.

10. (wang2025effectofnewborn pages 1-2): Xin Wang, Yun Sun, Xian-Wei Guan, Yan-Yun Wang, Dong-Yang Hong, Zhi-Lei Zhang, Ya-Hong Li, Pei-Ying Yang, Tao jiang, and Zheng-feng Xu. Effect of newborn genomic screening for lysosomal storage disorders: a cohort study in china. Genome Medicine, May 2025. URL: https://doi.org/10.1186/s13073-025-01483-z, doi:10.1186/s13073-025-01483-z. This article has 2 citations and is from a highest quality peer-reviewed journal.

11. (cohen2022inuteroenzymereplacement pages 12-14): Jennifer L. Cohen, Pranesh Chakraborty, Karen Fung-Kee-Fung, Marisa E. Schwab, Deeksha Bali, Sarah P. Young, Michael H. Gelb, Hamid Khaledi, Alicia DiBattista, Stacey Smallshaw, Felipe Moretti, Derek Wong, Catherine Lacroix, Dina El Demellawy, Kyle C. Strickland, Jane Lougheed, Anita Moon-Grady, Billie R. Lianoglou, Paul Harmatz, Priya S. Kishnani, and Tippi C. MacKenzie. In utero enzyme-replacement therapy for infantile-onset pompe’s disease. New England Journal of Medicine, 387:2150-2158, Dec 2022. URL: https://doi.org/10.1056/nejmoa2200587, doi:10.1056/nejmoa2200587. This article has 136 citations and is from a highest quality peer-reviewed journal.

12. (parenti2024theeuropeanreference pages 22-23): Giancarlo Parenti, Simona Fecarotta, Marianna Alagia, Federica Attaianese, Alessandra Verde, Antonietta Tarallo, Vincenza Gragnaniello, Athanasia Ziagaki, Maria Jose’ Guimaraes, Patricio Aguiar, Andreas Hahn, Olga Azevedo, Maria Alice Donati, Beata Kiec-Wilk, Maurizio Scarpa, Nadine A. M. E. van der Beek, Mireja Del Toro Riera, Dominique P. Germain, Hidde Huidekoper, Johanna M. P. van den Hout, Ans T. van der Ploeg, Ivo Baric, Spyros Batzios, Nadia Belmatoug, Andrea Bordugo, Annet M. Bosch, Anais Brassier, Alberto Burlina, David Cassiman, Brigitte Chabrol, Efstathia Chronopoulou, Maria Luz Couce-Pico, Niklas Darin, Anibh M. Das, Francois G. Debray, Patrick Deegan, Luisa M. de Abreu Freire Diogo Matos, Javier De Las Heras Montero, Maja Di Rocco, Dries Dobbelaere, Francois Eyskens, Ana Ferreira, Ana M. Gaspar, Serena Gasperini, Antonio González-Meneses López, Salvatore Grosso, Nathalie Guffon-Fouilhoux, Julia Hennermann, Tarekegn G. Hiwot, Simon Jones, Sandra Kingma, Veroniki Komninaka, Elena Martín-Hernández, Esmeralda Martins, Diana Miclea, György Pfliegler, Esmeralda Rodrigues, Dariusz Rokicki, Dominique Roland, Frank Rutsch, Alessandro Salviati, Ivailo Tournev, Kurt Ullrich, Peter M. van Hasselt, Suresh Vijay, Natalie Weinhold, Peter Witters, and Jiri Zeman. The european reference network for metabolic diseases (metabern) clinical pathway recommendations for pompe disease (acid maltase deficiency, glycogen storage disease type ii). Orphanet Journal of Rare Diseases, Nov 2024. URL: https://doi.org/10.1186/s13023-024-03373-w, doi:10.1186/s13023-024-03373-w. This article has 28 citations and is from a peer-reviewed journal.

13. (unnisa2022genetherapydevelopments pages 18-19): Zeenath Unnisa, John K. Yoon, Jeffrey W. Schindler, Chris Mason, and Niek P. van Til. Gene therapy developments for pompe disease. Biomedicines, 10:302, Jan 2022. URL: https://doi.org/10.3390/biomedicines10020302, doi:10.3390/biomedicines10020302. This article has 71 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.